Rani Therapeutics (RANI)

• Market cap: $23.9M
• 1 day: -1.01%
• 5 days: -0.08%
• 1 month: -5.91%
• 3 months: -10.87%
• 6 months: -67.35%
• Year to date: -65.78%
• 1 year: -79.1%
• 5 years: -95.46%
• 10 years: -95.46%
• Sector: Healthcare
• Industry: Biotechnology

About: Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Employees: 106

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

8.39% more ownership

Funds ownership: 10.84% [Q1] → 19.22% (+8.39%) [Q2]

3% more funds holding

Funds holding: 38 [Q1] → 39 (+1) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

28% less capital invested

Capital invested by funds: $4.58M [Q1] → $3.32M (-$1.26M) [Q2]

50% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 8